IMMUNOPRECISE ANTIBODIES ($IPA) is expected to release its quarterly earnings data on Friday, March 28th before market open, per Finnhub. Analysts are expecting revenue of $6,650,850 and earnings of -$0.08 per share.
You can see Quiver Quantitative's $IPA stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
IMMUNOPRECISE ANTIBODIES Hedge Fund Activity
We have seen 5 institutional investors add shares of IMMUNOPRECISE ANTIBODIES stock to their portfolio, and 5 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BANK OF MONTREAL /CAN/ removed 22,500 shares (-38.9%) from their portfolio in Q4 2024, for an estimated $9,263
- VIRTU FINANCIAL LLC added 20,759 shares (+inf%) to their portfolio in Q4 2024, for an estimated $8,546
- RENAISSANCE TECHNOLOGIES LLC added 17,900 shares (+29.7%) to their portfolio in Q4 2024, for an estimated $7,369
- UBS GROUP AG removed 12,232 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $7,816
- NORTHERN TRUST CORP removed 9,624 shares (-19.0%) from their portfolio in Q4 2024, for an estimated $3,962
- XTX TOPCO LTD added 7,724 shares (+49.3%) to their portfolio in Q4 2024, for an estimated $3,179
- GEODE CAPITAL MANAGEMENT, LLC removed 6,816 shares (-39.0%) from their portfolio in Q4 2024, for an estimated $2,806
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
